Skip to main
  1. Stocks
  2. Kalaris Therapeutics Inc
  3. Forecast
KLRS

KLRS Stock Forecast & Price Target

KLRS Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kalaris Therapeutics is viewed positively because TH103’s Phase 1a data showed a differentiated anti-VEGF profile, with treatment-naïve wet AMD patients achieving a 9-letter BCVA gain, a 118 µm CST reduction, and 29% remaining rescue-free through six months after one dose. The manufacturing issue appears batch-specific and manageable, with the company resolving it, planning new clinical supply in 2Q27, and retaining enough cash through the readout, which reduces near-term execution risk despite the Phase 1b/2 data shifting to 2H27. Fundamentally, the bullish case is supported by a large $15B+ wet AMD market, TH103’s design for stronger VEGF inhibition and retinal retention, and a credible path to roughly $1.6B of global sales by 2040 with meaningful upside from broader retinal indications.

Bears say

Kalaris Therapeutics is a single-asset, clinical-stage company whose valuation depends almost entirely on TH103, leaving it highly exposed if the program fails to show sufficient efficacy, safety, or durability. The missed drug supply specifications pushed key Phase 1b/2 wet AMD data to 2H27 from 1H27, extending development risk while the company still has no commercial products and likely will need additional capital, creating dilution pressure amid ongoing net losses. Even if approved, TH103 would enter a crowded retinal market against established therapies like Eylea and Vabysmo, as well as emerging long-acting competitors, so weak differentiation or limited market acceptance could materially cap future revenue.

KLRS has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kalaris Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

KLRS Analyst Forecast & Price Prediction

Get the latest KLRS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in KLRS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kalaris Therapeutics Inc (KLRS) Forecast

Analysts have given KLRS a Buy based on their latest research and market trends.

According to 4 analysts, KLRS has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kalaris Therapeutics Inc (KLRS)


KLRS Analyst Forecast & Price Prediction

Get the latest KLRS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in KLRS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover KLRS stock data and trends